Logo-ipp
Submitted: 09 Sep 2022
Accepted: 26 Jan 2023
ePublished: 17 Feb 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2024;10(1): e35458.
doi: 10.34172/ipp.2023.35458
  Abstract View: 328
  PDF Download: 182

Original

Evaluation of CD133 expression rate in colon cancers with immunohistochemistry method and its relationship with colon cancer prognosis

Mohammad Hossein Sanei 1 ORCID logo, Tina Foodeh 2* ORCID logo, Maryam Sanei 3 ORCID logo

1 Department of Pathology, Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Medical Student, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding Author: Tina Foodeh, Email: tinafoodeh@gmail.com

Abstract

Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, worldwide.

Objectives: This study aimed to evaluate the CD133 expression rate in colon cancers and determine its relationship with colon cancer prognosis.

Patients and Methods: This cross-sectional study was conducted in AL-Zahra hospital in Isfahan from April 2008 to April 2014 on 80 patients with CRC. In this study demographic profile such as age and gender, clinicopathologic profile including tumor grade, size, stage, metastasis, 5-year survival and their relation with CD133 expression in form of diffuse, weakly and negative were investigated.

Results: From the 80 investigated patients, 47 (58.8%) were male and rest were female. The most common type of CD133 was diffuse type with the 43.8% of cases. Mean age of patients was 61.4±14.12 years. This study showed a significant difference between type of CD133 in regards of tumour size (from 23.11 mm in negative cases to 38.85 in weakly cases, P = 0.047). Moreover, the 5-year survival in the three groups of CD133 were significantly different (from 22.54 months in diffuse to 34.42 months in negative cases, P = 0.025).

Conclusion: CD133 may be considered as an important tumor marker and a prognostic and diagnostic marker, as well as a therapeutic approach in patients with CRC.


Citation: Sanei MH, Foodeh T, Sanei M. Evaluation of CD133 expression rate in colon cancers with immunohistochemistry method and its relationship with colon cancer prognosis. Immunopathol Persa. 2024;10(1):e35458. DOI:10.34172/ ipp.2023.35458.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 329

Your browser does not support the canvas element.


PDF Download: 182

Your browser does not support the canvas element.